Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Adult
Disease Progression
Female
Humans
Imatinib Mesylate
/ therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Leukemia, Myeloid, Chronic-Phase
/ drug therapy
Male
Middle Aged
Pregnancy
Protein Kinase Inhibitors
/ therapeutic use
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Retrospective Studies
Safety-Based Drug Withdrawals
Treatment Outcome
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
08
10
2018
accepted:
27
02
2019
pubmed:
2
3
2019
medline:
24
7
2020
entrez:
2
3
2019
Statut:
ppublish
Résumé
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (
Identifiants
pubmed: 30819917
pii: haematol.2018.205054
doi: 10.3324/haematol.2018.205054
pmc: PMC6669161
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1589-1596Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Eur J Cancer. 2013 Oct;49(15):3242-6
pubmed: 23876833
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Haematologica. 2012 Jun;97(6):903-6
pubmed: 22180435
J Clin Oncol. 2014 Feb 10;32(5):424-30
pubmed: 24323036
Int J Epidemiol. 2016 Apr;45(2):565-75
pubmed: 27097747
Leukemia. 2015 May;29(5):999-1003
pubmed: 25652737
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Am J Hematol. 2015 Oct;90(10):910-4
pubmed: 26178642
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Curr Hematol Malig Rep. 2017 Oct;12(5):415-423
pubmed: 28944397
Epidemiology (Sunnyvale). 2016 Apr;6(2):
pubmed: 27274911
Cancer. 2017 Nov 15;123(22):4403-4410
pubmed: 28743166
Haematologica. 2016 Jun;101(6):717-23
pubmed: 26888022
Mol Clin Oncol. 2016 Jan;4(1):89-92
pubmed: 26870364
Leukemia. 2017 Jul;31(7):1525-1531
pubmed: 28218239
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Cancer. 2017 Jul 1;123(13):2482-2488
pubmed: 28241101
Lancet Haematol. 2015 May;2(5):e186-93
pubmed: 26688093
Acta Haematol. 2016;135(3):133-9
pubmed: 26535871
Lancet Haematol. 2015 Dec;2(12):e528-35
pubmed: 26686407
Am J Hematol. 2013 Jun;88(6):449-54
pubmed: 23440689
Blood. 2013 May 30;121(22):4439-42
pubmed: 23620577
Blood. 2007 Jan 1;109(1):58-60
pubmed: 16973963
Br J Haematol. 2017 Feb;176(4):669-671
pubmed: 26914729